Patients with chronic Hepatitis C are at risk of developing type 2 diabetes mellitus and impaired fasting glucose.
This risk may increase among Hepatitis C virus patients not responding to an antiviral therapy.
Dr Chiara Giordanino and colleagues from Italy compared the incidence of glucose abnormalities after an antiviral therapy between Hepatitis C virus patients with a long-term virological response and no responders.
The team assessed 202 Hepatitis C virus patients without the baseline glucose abnormalities enrolled in investigational trials or routinely treated with interferon/peginterferon with or without ribavirin from 1988 to 2001.
The available baseline sera were stored at -80°C.
|The risk of diabetes mellitus among the 202 Hep C patients was 17|
|American Journal of Gastroenterology|
The baseline data included age, sex, body mass index, viral load, genotype, liver histologic staging and steatosis, glucose, and cholesterol.
The homeostatic assessment of insulin resistance was calculated in the baseline serum.
The incidence of impaired fasting glucose or diabetes mellitus at the end of follow-up was compared between patients with long-term virological response and nonresponders.
The researchers found that after a median follow-up of 8 years, the cumulative risk of diabetes mellitus or impaired fasting glucose among the 202 Hepatitis C virus patients was 17%.
The 8-year risk was not significantly lower between long-term virological responses at 15% compared with 19% in nonresponders.
The team found that the hazard ratio adjusted for the baseline risk factors for diabetes mellitus and the predictors of a poor response was 0.88.
Among other factors, those more associated to impaired fasting glucose-diabetes mellitus were an increasing age, a higher body mass index, and a family history of diabetes mellitus.
Dr Giordanino’s team concluded, “After adjustment for several baseline risk factors, the incidence of glucose abnormalities was not significantly different between long-term virological responses and nonresponders.”
“These data suggest that Hepatitis C virus clearance does not significantly reduce the risk of glucose intolerance.”